Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by bendergardenon Jul 05, 2013 6:23pm
490 Views
Post# 21591850

A few big picture items to understand....

A few big picture items to understand....Most buying in the stock market is sector based:  investors will scoop up a baskety of companies if they believe the outlook for the sector is good.  They don't sit around and do bottom up analysis of this or that company to much degree, they just buy up a whack of them.  The rising etf market also magnifies this.  When a sector is deteriorating, they dump the lot.  You are going to bash your head against a brick wall repeatedly , and empty your account, by trying to fight this trend by arguing (to yourself , essentially) that your company won't be affected because of this or that detail, imagined upside etc.

The other side of the coin is,  that no one knows the gold market like gold companies.  A good deposit in a friendly jurisdiction will be snapped up like lightning.  There is no interest in Brigus by anyone. The simple fact is that it is a marginal ore body, in size, grade, return on investment, or any other metric you care to throw out there.  

The Saskatchewan property is/was worthless, as has been obvious since day one.

It's OK to own some shares, for fun, or whatever, but this has been basically a wretched investment.  I got out long ago, at about 1.65, having made about a 5% profit, or maybe it was 3%. Not much, but the fund were deployed elsewhere, to good use.

If you've had substantial  funds sitting in this, I would wonder if you've gotten lost in details , and missed the big picture?  Its your money.
Bullboard Posts